142
Participants
Start Date
April 30, 2015
Primary Completion Date
February 29, 2016
Study Completion Date
February 29, 2016
P-1037
P-1037 is a novel ENaC inhibitor
Hypertonic Saline
4.2% saline solution
Saline
0.17% saline solution
Long Island Jewish Medical Center, New Hyde Park
Albany Medical College, Albany
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Johns Hopkins University, Baltimore
University of Virginia Childrens, Charlottesville
University of North Carolina, Chapel Hill
Clinical Research of Charlotte, Charlotte
Medical University of South Carolina, Charleston
Anderson Pharmaceutical Research, Anderson
Univ of Florida Dept of Medicine, Gainesville
Central Florida Pulmonary Group, PA, Orlando
University of Miami Adult CF Center, Miami
New Lung Associates, Tampa
Vanderbilt University Medical Center, Nashville
Toledo Hospital, Toledo
Cincinnati Children's Hospital Medical Center, Cincinnati
Wayne State University/Harper University Hospital, Detroit
University of Wisconsin UW Hospital, Madison
Chicago Cystic Fibrosis Institute, Glenview
Washington University, St Louis
University of Kansas Medical Center, Kansas City
Tulane University Health Sciences Center, New Orleans
Santiago Reyes, Oklahoma City
UT Southwestern Medical Center, Dallas
Univ of Texas Health Science Center, Tyler
Alamo Clinical Research Associates, San Antonio
Austin Children's Chest Associates, Austin
Children's Hospital of Los Angeles, Los Angeles
Maine Medical Center, Portland
UMass Memorial medical Center, Worcester
Dartmouth Hitchcock Medical Center, Lebanon
Rutgets-Robert Wood Johnson Medical School, New Brunswick
Pediatric Pulmonology/Cystic Fibrosis, Somerville
Lead Sponsor
Vertex Pharmaceuticals Incorporated
INDUSTRY
Parion Sciences
INDUSTRY